Not yet recruitingPhase 2NCT07501052

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sam Chun Dang Pharm. Co. Ltd.
Principal Investigator
Byung Jhip Ha
Sam Chun Dang Pharm. Co. Ltd.
Intervention
SCD411 0.05mL (2mg)(drug)
Enrollment
33 enrolled
Eligibility
18 years · All sexes
Timeline
20262026

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07501052 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials